- Home
- APGE vs PCH Comparison
APGE vs PCH Comparison
Compare APGE & PCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- PCH
- Stock Information
- Founded
- APGE 2022
- PCH 1903
- Country
- APGE United States
- PCH United States
- Employees
- APGE N/A
- PCH N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- PCH Real Estate Investment Trusts
- Sector
- APGE Health Care
- PCH Real Estate
- Exchange
- APGE Nasdaq
- PCH Nasdaq
- Market Cap
- APGE 3.0B
- PCH 3.3B
- IPO Year
- APGE 2023
- PCH N/A
- Fundamental
- Price
- APGE $47.25
- PCH $41.77
- Analyst Decision
- APGE Strong Buy
- PCH Buy
- Analyst Count
- APGE 5
- PCH 5
- Target Price
- APGE $75.20
- PCH $48.50
- AVG Volume (30 Days)
- APGE 366.5K
- PCH 420.1K
- Earning Date
- APGE 11-12-2024
- PCH 10-28-2024
- Dividend Yield
- APGE N/A
- PCH 4.31%
- EPS Growth
- APGE N/A
- PCH N/A
- EPS
- APGE N/A
- PCH 0.20
- Revenue
- APGE N/A
- PCH $1,058,432,000.00
- Revenue This Year
- APGE N/A
- PCH N/A
- Revenue Next Year
- APGE N/A
- PCH $1.14
- P/E Ratio
- APGE N/A
- PCH $210.26
- Revenue Growth
- APGE N/A
- PCH 3.49
- 52 Week Low
- APGE $16.39
- PCH $37.06
- 52 Week High
- APGE $72.29
- PCH $50.04
- Technical
- Relative Strength Index (RSI)
- APGE 35.00
- PCH 44.65
- Support Level
- APGE $57.85
- PCH $41.00
- Resistance Level
- APGE $63.50
- PCH $42.78
- Average True Range (ATR)
- APGE 3.86
- PCH 1.12
- MACD
- APGE -0.90
- PCH 0.02
- Stochastic Oscillator
- APGE 4.97
- PCH 52.84
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
About PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.